Sanofi/REGN Commence Enrollment - Analyst Blog

By
A A A

Sanofi ( SNY ) and partner Regeneron Pharmaceuticals, Inc. ( REGN ) recently announced that they started enrolling patients for two phase III trials (SARIL-RA COMPARE and SARIL-RA ASCERTAIN) on their rheumatoid arthritis (RA) candidate, sarilumab.

The 24-week, multi-center, randomized, double-blind and active-calibrator SARIL-RA ASCERTAIN study (n = 200) will evaluate the safety and efficacy of sarilumab and Actemra (tocilizumab) in combination with methotrexate (MTX) in patients with RA who received inadequate treatment benefit from tumor necrosis factor alpha (TNF-alpha) inhibitors.

Meanwhile, the multi-center, randomized, double-blind and active-control SARIL-RA COMPARE trial will assess the safety and efficacy of sarilumab in combination with MTX versus Amgen Inc. 's ( AMGN ) Enbrel (etanercept). The trial will enroll 700 patients suffering from moderate-to-severe RA who demonstrated an insufficient response to Humira (adalimumab) as first TNF-alpha inhibitor treatment.

We note that Sanofi and Regeneron are conducting a SARIL-RA phase III development program to evaluate the use of sarilumab in the RA indication. The program consists of five trials, namely, SARIL-RA MOBILITY, SARIL-RA TARGET, SARIL-RA COMPARE, SARILRA ASCERTAIN and SARIL-RA EXTEND.

SARIL-RA MOBILITY, the most advanced phase III trial in the SARIL-RA program, has enrolled 1,197 patients. The data from the trial is expected to be released in the first half of 2014.

Sanofi carries a Zacks Rank #3 (Hold). Sanofi is looking to combat the generic threat confronting most of its key drugs by signing deals and making acquisitions. We are pleased with Sanofi's efforts to develop its pipeline and believe that newly approved products in Sanofi's portfolio hold huge commercial potential.

Stocks that look better placed at present include Isis Pharmaceuticals, Inc. ( ISIS ), which carries a Zacks Rank #2 (Buy).



AMGEN INC (AMGN): Free Stock Analysis Report

ISIS PHARMACEUT (ISIS): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AMGN , ISIS , MTX , REGN , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Can Magnets Relieve Pain?
Can Magnets Relieve Pain?           
The Danger of Small ETFs
The Danger of Small ETFs            

Stocks

Referenced

Most Active by Volume

26,726,831
  • $16.2385 ▼ 0.56%
22,612,021
  • $74.8701 ▼ 1.43%
20,229,310
  • $101.879 ▲ 0.98%
19,848,841
  • $3.595 ▲ 0.98%
15,751,867
  • $47.81 ▼ 0.75%
14,216,482
  • $18.7731 ▲ 2.98%
13,567,194
  • $38.08 ▲ 0.77%
12,555,761
  • $10.285 ▼ 3.79%
As of 8/27/2014, 12:31 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com